Management of Metastatic Bone Disease Algorithms for Diagnostics and Treatment

被引:4
作者
Jehn, Christian F. [1 ]
Diel, Ingo J.
Overkamp, Friedrich
Kurth, Andreas [2 ]
Schaefer, Reinhold
Miller, Kurt [3 ]
Lueftner, Diana [1 ]
机构
[1] Univ Hosp Charite, Dept Hematol Oncol & Tumor Immunol, Berlin, Germany
[2] THEMISTOCLES GLUCK Hosp Ratingen, Ratingen, Germany
[3] Univ Hosp Charite, Dept Urol, Berlin, Germany
关键词
Metastatic bone disease; algorithm for diagnostic and treatment; bone-targeted agents; skeletal morbidity; multidisciplinary management; vertebral bone metastasis; non-vertebral bone metastasis; review; SKELETAL-RELATED EVENTS; PROSTATE-CANCER; BREAST-CANCER; ZOLEDRONIC ACID; SOLID TUMORS; DOUBLE-BLIND; ANDROGEN-DEPRIVATION; DENOSUMAB; BISPHOSPHONATES; COMPLICATIONS;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Bone is a frequent site of metastases in advanced cancer and is associated with significant skeletal morbidity. Current treatment options are aimed at preserving and improving functional independence and quality of life. Materials and Methods: A review of current literature focusing on diagnostic tools and treatment approaches of bone metastasis in advanced cancer was performed and conclusions were incorporated into diagnostic and treatment algorithms. Results: Radiologic imaging has added valuable tools for screening and diagnostics of bone metastasis. Clinical management of skeletal metastasis includes improved pain management, introduction of bone modifying agents and advancements in surgical and radiation therapy. We propose three algorithms enhancing the sensitivity of diagnostics and improving multidisciplinary management of vertebral and non-vertebral bone metastasis. Conclusion: Bone metastases are an expression of a systemic disease. Treatment options include highly specialized modalities yet need to be tailored to individual needs. Algorithms help standardize treatment procedures and can improve treatment outcome in a multidisciplinary setting.
引用
收藏
页码:2631 / 2637
页数:7
相关论文
共 56 条
[1]  
Allan Alison L, 2006, Breast Dis, V26, P87
[2]   Current use of bisphosphonates in oncology [J].
Body, JJ ;
Bartl, R ;
Burckhardt, P ;
Delmas, PD ;
Diel, IJ ;
Fleisch, H ;
Kanis, JA ;
Kyle, RA ;
Mundy, GR ;
Paterson, AHG ;
Rubens, RD .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (12) :3890-3899
[3]  
Buckwalter JA, 1997, AM FAM PHYSICIAN, V55, P1761
[4]   Pharmacoeconomics of Bisphosphonates for Skeletal-Related Event Prevention in Metastatic Non-Breast Solid Tumours [J].
Carter, John A. ;
Joshi, Avani D. ;
Kaura, Satyin ;
Botteman, Marc F. .
PHARMACOECONOMICS, 2012, 30 (05) :373-386
[5]   Risk of mortality following clinical fractures [J].
Cauley, JA ;
Thompson, DE ;
Ensrud, KC ;
Scott, JC ;
Black, D .
OSTEOPOROSIS INTERNATIONAL, 2000, 11 (07) :556-561
[6]   Estrogen and bone health in men and women [J].
Cauley, Jane A. .
STEROIDS, 2015, 99 :11-15
[7]   Muscle and bone effects of androgen deprivation therapy: current and emerging therapies [J].
Cheung, Ada S. ;
Zajac, Jeffrey D. ;
Grossmann, Mathis .
ENDOCRINE-RELATED CANCER, 2014, 21 (05) :R371-R394
[8]   Palliative radiotherapy trials for bone metastases: A systematic review [J].
Chow, Edward ;
Harris, Kristin ;
Fan, Grace ;
Tsao, May ;
Sze, Wai M. .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (11) :1423-1436
[9]  
Chow Edward, 2007, Curr Opin Support Palliat Care, V1, P11, DOI 10.1097/SPC.0b013e328133f5d8
[10]   Emerging therapies in bone metastasis [J].
Clement-Demange, Lise ;
Clezardin, Philippe .
CURRENT OPINION IN PHARMACOLOGY, 2015, 22 :79-86